Physician profile
Paul Daugherty
NPI 1144383738
$1,736.01
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $537 · 2021: $460.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $670.88 | 2019-2021 | |
| Novo Nordisk INC | $199.74 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $149.62 | 2019-2021 | |
| Glaxosmithkline, LLC. | $112.49 | 2019-2021 | |
| Astellas Pharma US INC | $99.00 | 2021 | |
| Amarin Pharma, INC. | $76.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $66.88 | 2019-2020 | |
| Lilly USA, LLC | $59.83 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $51.34 | 2019-2020 | |
| Pfizer INC. | $50.97 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $50.24 | 2020-2021 | |
| Eisai INC. | $37.23 | 2020 | |
| Esperion Therapeutics, INC. | $34.76 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $26.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.70 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.26 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.